News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Allos Therapeutics, Inc.'s Cancer Drug, Folotyn Extends Lung Cancer Survival
July 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Allos Therapeutics Inc said its cancer drug improved the survival of patients with advanced non-small lung cancer in a mid-stage trial.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Weight loss
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
March 9, 2026
·
2 min read
·
Annalee Armstrong
Breast cancer
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
March 9, 2026
·
2 min read
·
Annalee Armstrong
Drug Development
Xenon To Seek Approval of First-in-Class Epilepsy Drug After Exceeding Phase 3 Expectations
March 9, 2026
·
3 min read
·
Heather McKenzie
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
March 9, 2026
·
2 min read
·
Tristan Manalac
